We are live on ! Find out more
FCMI

Foresite Capital Management II Portfolio holdings

AUM $29.2M
1-Year Est. Return 44.84%
This Fund
S&P 500
This Quarter Est. Return
-15.71%
1 Year Est. Return
+44.84%
3 Year Est. Return
-66.21%
5 Year Est. Return
-36.36%
10 Year Est. Return
–
AUM
$329M
AUM Growth
+$44.4M
Cap. Flow
+$128M
Cap. Flow %
38.78%
Top 10 Hldgs %
82.37%
Holding
31
New
9
Increased
7
Reduced
4
Closed
2

Top Buys

Rank Stock Value
1
AIMT
Aimmune Therapeutics
AIMT
+$95.6M
2
RGLS
Regulus Therapeutics
RGLS
+$7.33M
3
XLRN
Acceleron Pharma
XLRN
+$5.04M
4
RGNX icon
Regenxbio
RGNX
+$4M
5
EPZM
Epizyme, Inc
EPZM
+$2.26M

Top Sells

Rank Stock Value
1
JUNO
Juno Therapeutics, Inc.
JUNO
+$4.88M
2
SCYX icon
SCYNEXIS
SCYX
+$2.23M
3
BITI
BIOTIE THERAPIES CORP SPONSORED ADR
BITI
+$1.9M
4
AGRX
Agile Therapeutics
AGRX
+$428K
5
QTNT
Quotient Limited Ordinary Shares
QTNT
+$111K

Sector Composition

Rank Sector Weight
1 Healthcare 58.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NDRM
26
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$1.59M 0.48%
76,801
+2,416
+3% +$49.6K
BITI
27
DELISTED
BIOTIE THERAPIES CORP SPONSORED ADR
BITI
$1.06M 0.32%
80,883
-108,017
-57% -$1.9M
SIOX
28
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$840K 0.26%
8,125
– –
OREX
29
CALL
DELISTED
Orexigen Therapeutics, Inc.
OREX
$179K 0.05%
8,500
-3,500
-29% -$120K
AGRX
30
DELISTED
Agile Therapeutics
AGRX
– –
-25
Closed -$428K
JUNO
31
DELISTED
Juno Therapeutics, Inc.
JUNO
– –
-91,575
Closed -$4.88M
1
2

Similar funds

AG
Appleton Group Appleton, Wisconsin $28.6M AUM 32.21% 1-Year Est. Return
SAM
Sandbar Asset Management London, United Kingdom $30.5M AUM 46.07% 1-Year Est. Return
AC
Amia Capital London, United Kingdom $32.1M AUM 0.56% 1-Year Est. Return
QI
Qualcomm Inc San Diego, California $32.1M AUM 5.35% 1-Year Est. Return
TAAM
Top Ace Asset Management Hong Kong $25.3M AUM 23.27% 1-Year Est. Return
NAM
Nationwide Asset Management Columbus, Ohio $25.1M AUM 13.37% 1-Year Est. Return
MSKCC
Memorial Sloan Kettering Cancer Center New York $24.6M AUM 10.16% 1-Year Est. Return
BRC
Bishop Rock Capital New York $24.3M AUM 20.73% 1-Year Est. Return

Foresite Capital Management II's Q3 2015 Portfolio in Review

As of Q3 2015, Foresite Capital Management II held 31 positions worth $329M, up 16% from $285M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Foresite Capital Management II deployed $128M of net new capital in Q3 2015, opening 9 new positions and adding to 7 existing holdings. Its largest new stake was Aimmune Therapeutics: 4,087,900 shares worth $104M.

By sector, the portfolio is most concentrated in Healthcare at 58% of assets, down from 92% a quarter earlier.

On the sell side, the largest reduction was SCYNEXIS, an estimated $2.23M trimmed.

  • Foresite Capital Management II's largest Q3 2015 buy was Aimmune Therapeutics: 4,087,900 shares worth $104M.
  • Foresite Capital Management II added most to Regulus Therapeutics in Q3 2015, an estimated $7.33M increase.
  • Foresite Capital Management II's biggest Q3 2015 reduction was SCYNEXIS, cutting an estimated $2.23M.
  • Foresite Capital Management II fully exited Juno Therapeutics, Inc. in Q3 2015, selling an estimated $4.88M.
  • Foresite Capital Management II's ten largest holdings make up 82% of its $329M portfolio in Q3 2015.
  • Foresite Capital Management II opened 9 new positions and closed 2 in Q3 2015.
  • Foresite Capital Management II's portfolio value rose 16% quarter-over-quarter to $329M.

Based on Foresite Capital Management II's 13F filing for Q3 2015, filed 13 Nov 2015.